Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...
New funding led by Goldcrest Capital and Godfrey Capital to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies JUN_01 would be the first ever candidate to ...
Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...
Wholesale food distributor Sirna & Sons Produce of Ravenna plans to lay off 45 workers from its distribution facility in Norwalk. The company disclosed the planned layoffs, scheduled for December, in ...
Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. In this study, we developed a fluorinated dendrimer exhibiting ...
Background: Investigated within the endometrial carcinoma (EC) context, Snail-1 emerges as a pivotal transcription factor governing invasion and metastasis by orchestrating epithelial-to-mesenchymal ...
Glioblastoma multiforme (GBM) is the most common type of primary brain tumor in adults and has a poor prognosis. Small interfering RNA (siRNA) can disrupt different mechanisms involved in the genesis ...
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...
Chronic hepatitis B (CHB) remains a significant global health burden, with existing therapies including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines demonstrating limited success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback